title: Did animal offer relevant model for Bevacizumab testing?
authors.forename: C
authors.initials: C
authors.lastname: Eveno
authors.forename: S
authors.initials: S
authors.lastname: Gaujoux
authors.forename: G
authors.initials: G
authors.lastname: Tobelem
authors.forename: M
authors.initials: M
authors.lastname: Pocard
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004195:Disease Models, Animal; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D051379:Mice; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab